1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
FUJIFILM Holdings Corporation

FUJIFILM Holdings Corporation

FUJIY
FUJIFILM Holdings CorporationUS flagOther OTC
11.14
USD
-0.03
- -
26.64BMarket Cap
FUJIFILM Holdings Corporation
FUJIY
(Other OTC)

Recent

price

11.14

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
759.81
759.56
766.24
843.84
861.82
880.8
871.93
929.98
958.96
945.23
914.09
1,051.39
396.32
1,229.55
1,326.76
1,394.5
- -
Revenue per Share
21.88
15.14
18.78
28.01
40.99
41.67
49.38
53.77
54.47
51.03
75.55
87.91
30.42
101.12
108.33
114.96
- -
Basic EPS, GAAP
29.18
4.62
30.94
68.36
62.32
49.19
71.96
68.63
63.23
59.59
123.1
65.78
-15.67
-23.57
-23.57
-66.47
- -
Free Cash Flow per Basic Share
4.61
5.42
6.25
6.67
9.17
11.45
11.33
12.12
13.08
14.62
15.83
17.91
6.39
23.33
23.32
35.04
- -
Dividend per Share
657.2
686.77
698.85
718.25
749.05
793.08
869.61
926.46
1,004.94
1,062.94
1,143.65
1,210.58
368.26
1,155.16
1,233.22
1,311.75
1,310.17
Book Value per Share
501.11
490.98
526.69
585.42
650.77
586.71
635.23
603.84
569.63
475.46
537.59
644.48
247.48
847.6
932.94
1,119.99
1,118.64
Tangible Book Value per Share
2,918
2,890
2,890
2,891
2,892
2,793
2,663
2,617
2,536
2,449
2,399
2,402
7,214
2,408
2,409
2,407
2,410
Basic Weighted Avg Shares
2,217,084
2,195,293
2,214,696
2,439,953
2,492,605
2,460,383
2,322,163
2,433,365
2,431,489
2,315,141
2,192,519
2,525,773
2,859,041
2,960,916
3,195,828
3,356,969
- -
Sales/Revenue/Turnover
7.58
5.15
5.15
5.77
6.92
7.34
7.42
5.07
8.63
8.06
7.55
9.09
9.55
9.35
10.33
10.43
- -
Operating Margin (%)
157,094
147,775
141,548
141,440
122,909
124,960
117,635
127,642
129,932
122,653
123,423
132,999
142,215
150,014
150,014
172,371
- -
Depreciation Expense
63,852
43,758
54,266
80,996
118,553
116,402
131,506
140,694
138,106
124,987
181,205
211,180
219,422
243,509
260,951
276,735
- -
Net Income, GAAP
41.01
33.67
37.53
34.8
29.67
26.58
22.65
27.52
26.35
20.87
23.58
21.94
23.1
24.62
22.78
24.89
- -
Effective Tax Rate (%)
2.88
1.99
2.45
3.32
4.76
4.73
5.66
5.78
5.68
5.4
8.26
8.36
7.67
8.22
8.17
8.24
- -
Profit Margin (%)
724,385
629,624
1,014,923
1,165,275
1,320,930
1,159,440
1,354,622
1,196,585
1,028,621
829,196
791,092
745,154
740,785
408,787
455,741
460,761
460,761
Working Capital
119,314
20,334
317,592
314,968
313,045
310,388
434,843
412,502
353,533
555,823
494,297
303,967
325,460
257,939
555,600
702,551
702,551
LT Debt
1,850,871
1,856,484
2,024,786
2,198,223
2,467,416
2,231,997
2,268,058
2,298,706
2,244,841
1,993,757
2,222,157
2,524,940
2,787,860
3,173,315
3,352,682
3,844,385
3,844,385
Total Equity
4.72
3.67
3.21
3.69
4.46
4.85
4.87
3.17
5.55
5.33
4.53
6.06
6.59
5.86
6.36
5.77
- -
Return on Invested Capital (%)
2.51
1.44
1.65
2.43
3.83
3.68
4.05
4.53
3.81
3.41
5.38
6.1
6.69
7.65
7.45
7.03
- -
Return on Capital (%)
3.34
2.24
2.71
3.95
5.59
5.31
5.8
5.94
5.56
4.85
6.78
7.47
7.89
8.96
9.07
9.03
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
254,768
- -
324,462
LT Borrowings
571,872
- -
607,034
LT Finance Leases
96,176
- -
95,517
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,205
- -
1,205
Market Capitalization
4,402,656
3,992,451
3,647,066

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
1,600,471
- -
1,719,033
Cash, Cash Equivalents & STI
160,878
- -
170,553
Accounts Receivable, Net
643,838
- -
742,721
Inventories
600,118
- -
600,796
Total Current Liabilities
1,156,321
- -
1,258,272
Payables & Accruals
- -
- -
- -
ST Debt
254,768
- -
324,462
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.91%
11.64%
14.67%
Free Cash Flow
- -
- -
181.85%
Net Income, GAAP
9.82%
8.93%
6.05%
Sales/Revenue/Turnover
3.39%
8.98%
5.04%
Total Cash Common Dividend
- -
- -
50.18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
660,759
727,711
766,941
805,505
2,960,916
2025
- -
- -
- -
- -
3,195,828
2026
- -
- -
- -
- -
3,356,969

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22.62
24.59
25
- -
101.12
2025
- -
- -
- -
- -
108.33
2026
- -
- -
- -
- -
114.96

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11.67
- -
11.67
- -
23.33
2025
- -
- -
- -
- -
23.32
2026
- -
- -
- -
- -
35.04
Similar Companies
Health Logic Interactive Inc. (CHYPF)
Shanghai Sanyou Medical Co., Ltd. (688085.SS)
Medicalgorithmics S.A. (MDG.WA)
Glaukos Corporation (GKOS)
Ambu A/S (AMBFF)
Medistim ASA (0OCD.L)
Business
FUJIFILM Holdings Corporation, founded in 1934 and headquartered at 7-3 Akasaka 9-chome, Minato-ku, Tokyo, Japan, operates as a holding company overseeing products and services across healthcare, electronics, business innovation, and imaging segments worldwide, including Japan, the United States, Europe, Asia, and other regions. The healthcare segment encompasses medical systems such as endoscopes and imaging diagnostics, bio-CDMO services for biopharmaceuticals including antibodies, cell and gene therapies, and life science solutions for drug discovery support; the electronics segment provides semiconductor materials, display materials like optical films for flat-panel displays, and other electronics materials; the business innovation segment offers business solutions, office solutions including multifunction devices, printers, and document outsourcing, as well as graphic communications equipment; and the imaging segment delivers consumer imaging products like Instax instant cameras, digital cameras, color films, and professional imaging including broadcast lenses, cinema lenses, and surveillance cameras. Recent developments include the completion of a new building for advanced semiconductor materials in Shizuoka in November 2025, the launch of joint research with Japan's National Cancer Center in November 2025 to advance innovative cancer treatments, the expansion of its strategic partnership with argenx SE in September 2025 to include U.S. manufacturing operations at its Holly Springs site starting in 2028, the divestiture of its Irvine Scientific medical media business to Astorg in September 2025, and plans to open new NURA health screening centers in Vietnam, Thailand, the Philippines, and Malaysia in October 2025, alongside the introduction of the FUJIFILM Prescale Station product in October 2025.

Company News

APIChatGPT

  • businesswire.com

    Fujifilm Opens New Endoscopy Warehouse Facility in Fairfield, NJ, Expanding Service Operations and Supporting Continued Business Growth

  • businesswire.com

    Fujifilm Life Sciences at BIO 2026

  • businesswire.com

    Fujifilm to Debut New ZUH12000 Projector and Showcase Fully Immersive 360° Booth Experience at InfoComm 2026

  • businesswire.com

    New Color Capabilities, New Tech: Fujifilm Launches Flagship REVORIA PRESS™ PC2120

  • businesswire.com

    Two Fujifilm Production Color Printers Win Red Dot Design Award: Product Design 2026

  • businesswire.com

    Fujifilm Presents Latest Advanced Packaging Research Results and Will Introduce PFAS-Free PBO at ECTC 2026

  • businesswire.com

    Fujifilm and mTuitive Forge Partnership to Advance Precision Medicine

  • businesswire.com

    FUJIFILM Cellular Dynamics Launches New iPSC Manufacturing Facility in Madison

  • businesswire.com

    Fujifilm Hits The Road to Engage with Consumers Nationwide on its 2026 FUJIFILM instax™ Capture the Joy Tour

  • businesswire.com

    Fujifilm Launches the EB-710US, a Novel Next-Generation, Balloon-less Endobronchial Ultrasound (EBUS) Bronchoscope for Pulmonary Care

  • zacks.com

    FUJIFILM Q4 Earnings & Revenues Up Y/Y on Solid Segmental Performance

  • businesswire.com

    Fujifilm's ELUXEO 8000® Endoscopic Imaging System in Combination with 840TP Gastroscope Wins 2026 MedTech Breakthrough Award

  • businesswire.com

    FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media

  • zacks.com

    Are Investors Undervaluing Fujifilm (FUJIY) Right Now?

  • businesswire.com

    Fujifilm Named 2026 TIME100 Influential Company & Industry Leader

  • businesswire.com

    Fujifilm to Demonstrate its Leading-Edge Endoscopic Imaging Innovations at the Digestive Disease Week (DDW®) 2026 Conference

  • businesswire.com

    Fujifilm's Taisuke Fujita Honored with Prestigious ASGE Crystal Award for Contributions to the Advancement of Endoscopic Care

  • businesswire.com

    Fujifilm Powers U.S. and Canadian Operations with 100% Renewable Energy through Solar Partnership

  • businesswire.com

    Fujifilm Introduces the Next Generation in Photo Printing Experiences: instax SPOT™ Photobooth and Print Station

  • businesswire.com

    Virica Biotech and FUJIFILM Biosciences Collaborate Under the Canada–Japan Co‑Innovation Program to Advance AAV Production Enhancers